NCT06392126View on ClinicalTrials.gov

Personalized Antisense Oligonucleotide Therapy for A Single Participant With CHCHD10 ALS

PHASE1/PHASE2Active, not recruitingINTERVENTIONAL

Enrollment

1

Participants

Timeline

Start Date

April 16, 2024

Primary Completion Date

April 30, 2026

Study Completion Date

April 30, 2026

Conditions

Amyotrophic Lateral Sclerosis

Interventions

DRUG

nL-CHCHD-001

Personalized antisense oligonucleotide

Trial Locations (1)

32224

Mayo Clinic, Jacksonville

Sponsors

Collaborators (1)

All Listed Sponsors

collaborator

Mayo Clinic

OTHER

lead

n-Lorem Foundation

OTHER

NCT06392126 - Personalized Antisense Oligonucleotide Therapy for A Single Participant With CHCHD10 ALS | Biotech Hunter | Biotech Hunter